24/7 Market News Snapshot 08 October, 2025 – Nexalin Technology, Inc. Common Stock (NASDAQ:NXL)

October 8, 2025

DENVER, Colo., 08 October, 2025 (www.247marketnews.com) – (NASDAQ:NXL) are discussed in this article.
Nexalin Technology, Inc. has recently experienced a significant increase in its stock price, with shares climbing to $1.218 in pre-market trading, representing a 29.82% rise from the previous close of $0.938. This surge is backed by a trading volume of 8.06 million shares, signaling robust investor interest and a bullish sentiment towards the company. Market analysts are noting a favorable breakout trend in the stock’s price action, suggesting that further gains could be on the horizon as market momentum builds.

Simultaneously, Nexalin has announced encouraging findings from a recent randomized, sham-controlled clinical trial that highlights its proprietary technology’s efficacy. This trial focused on the cognitive performance and brain connectivity improvements among patients with mild Alzheimer’s disease (AD), leveraging Nexalin’s advanced 15 milliamp (mA) Gen-2 Deep Intracranial Frequency Stimulation (DIFS™). Results published in the journal Radiology reveal statistically significant enhancements in cognitive abilities, as evidenced by improved scores on the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) assessments.

Moreover, neuroimaging studies demonstrated increased functional connectivity between the hippocampus and critical cortical regions, essential for memory and executive functions, alongside network-level improvements across broader cognitive systems often affected by AD. Importantly, no adverse effects were reported during the trial, further establishing the safety profile of Nexalin’s innovative therapy.

CEO Mark White emphasized the study’s importance, stating that it endorses the mission to deliver non-invasive alternatives for managing neurodegenerative conditions. With the Alzheimer’s market anticipated to exceed $20 billion annually, Nexalin’s technology represents a promising step in addressing significant mental health challenges while bolstering the company’s growth trajectory within the neurostimulation sector.

Related news for (NXL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.